|
|
|
Role of visible light-activated photocatalyst on the reduction of anthrax spore-induced mortality in mice
From PLoS ONE, published online Jan 9
|
|
|
Detection of anthrax toxin by an ultrasensitive immunoassay using Europium nanoparticles
From Clin Vaccine Immunol, published online Jan 7
|
|
|
Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007
|
|
|
Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax
From Infect Immun, published online Dec 29
|
|
|
A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics
From J Infect Dis, published online Dec 19
|
|
|
Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine
From J Infect Dis, published online Dec 19
|
|
|
Investigations and control measures following a case of inhalation anthrax in East London in a drum maker and drummer, October 2008
|
|
|
Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax
|
|
|
Anthrax: Current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis
CIDRAP-authored overview, updated Nov 3 with new research
|
|
|
Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?
From Nov Antimicrob Agents Chemother
|
|
|
Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax
From Infect Immun, published online Oct 13
|
|
|
Amoxicillin for postexposure inhalational anthrax in pediatrics: rationale for dosing recommendations
From Pediatr Infect Dis, published online Oct 1
|
|
|
Cathelicidin administration protects mice from Bacillus anthracis spore challenge
|
|
|
The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-specific CD4+ T cells with a phenotype distinct from that of naive PA T cells
|
|
|
Why do UK military personnel refuse the anthrax vaccination?
From Biosecur Bioterr, published online Sep 17
|
|
|
Cross-contamination of clinical specimens with Bacillus anthracis during a laboratory proficiency test--Idaho, 2006
|
|
|
Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women
From Pharmacoepidemiol Drug Saf, published online Sep 10
|
|
|
AHRQ Hospital Surge Model
Estimates hospital resources needed for disease or terror attack; released Sep 12
|
|
|
Potentiation of an anthrax DNA vaccine with electroporation
|
|
|
An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague, and staphylococcal toxic shock
From J Immune Based Ther Vaccines, published online Sep 3
|
|
|
In vivo demonstration and quantification of intracellular Bacillus anthracis in lung epithelial cells
|
|
|
Responding to a bioterrorism attack--one scenario: part 1
From Jul/Sep Health Care Manag (Frederick)
|
|
|
Anthrax toxins inhibit neutrophil signalling pathways in brain endothelium and contribute to pathogenesis of meningitis
From PLoS ONE, published online Aug 13
|
|
|
Nosocomial infection of Serratia marcescens may induce a protective effect in monkeys exposed to Bacillus anthracis
|
|
|
Gamma irradiation can be used to inactivate Bacillus anthracis spores without compromising the sensitivity of diagnostic assays
From Jul Appl Environ Microbiol
|
|
|
Birth defects among infants born to women who received anthrax vaccine in pregnancy
From Am J Epidemiol, published online Jul 2
|
|
|
Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background
From Jul Clin Vaccine Immunol
|
|
|
Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax
From Antimicrob Agents Chemother, published online Jul 7
|
|
|
Occurrence and genetic diversity of Bacillus anthracis strains isolated in an active wool-cleaning factory
From Jul Appl Environ Microbiol
|
|
|
Analysis of suspicious powders following the post 9/11 anthrax scare
|
|
|
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis
From Jun Antimicrob Agents Chemother
|
|
|
Cutaneous anthrax associated with drum making using goat hides from West Africa--Connecticut, 2007
|
|
|
Inhalation anthrax: dose response and risk analysis
From Jun Biosecur Bioterror
|
|
|
Modeling the incubation period of inhalational anthrax
From Med Decis Making, published online Jun 12
|
|
|
Human serum contains a protease that protects against cytotoxic activity of Bacillus anthracis lethal toxin in vitro
From Jun Clin Vaccine Immunol
|
|
|
Anthrax: Current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis
CIDRAP-authored overview updated May 30 with new research
|
|
|
Inactivation of Bacillus anthracis spores by a combination of biocides and heating under high-temperature short-time pasteurization conditions
From Jun Appl Environ Microbiol
|
|